United States Patent 5,840,684: Scope, Claims, and Landscape for A82846B-Based Antibiotics

United States Patent 5,840,684 claims a defined class of A82846B-derived antibacterial compounds, specific composition positioning on the vancosamine sugar amino group, and treatment and preparation methods aimed at vancomycin-resistant enterococci (VRE). Scope concentrates on (i) the compound structure (claim 1), (ii) a composition defined by that compound attached at a specific glycosyl location (claim 2), and (iii) two process pathways that convert A82846B using 4’-chlorobiphenylcarboxaldehyde via a Schiff base that is then reduced (claims 5-7). The patent landscape (based on the claim architecture and typical prosecution strategy for A82846B derivatives) clusters around: (a) other A82846B substitutions on the same sugar handles, (b) alternative aldehydes or reductive conditions that change the attached aryl group or reduction step, and (c) method-of-treatment claims targeted to Gram-positive and VRE indications.

What is claimed in US 5,840,684?

Claim 1: Which compounds are within scope?

Claim 1 is a structural formula claim:

“A compound of the formula: [structure] or a salt thereof.”

Even without the chemical rendering in the text extract, the rest of the claims constrain what that formula represents in practice. Claims 2 and 5-7 identify the key substituent and attachment logic:

A82846B is the precursor scaffold referenced in claims 2 and 5-6.
The aryl substituent is tied to “4’-chlorobiphenylcarboxaldehyde” (claims 5-6).
The aryl fragment attaches through a reaction that proceeds via a Schiff’s base (claims 5-6), then reduces (claim 5-7).
Claim 2 states the attachment happens “on the amino group of the 4-epi-vancosaminyl sugar of the 4-epi-vancosaminyl-O-glycosyl disaccharide.”

Practical scope implication: Claim 1 reads as a structural capture of the specific A82846B-derived arylamine product formed by reductive amination of the sugar amino group using 4’-chlorobiphenylcarboxaldehyde. Because it is a formula claim, infringement analysis for claim 1 typically turns on structural equivalence of the final product (and salt inclusion), not the synthesis route.

Claim 2: How is the composition defined and where does the substituent go?

Claim 2 is a composition claim with a strong structural-location constraint:

“A pharmaceutical composition comprising 4 4 chlorophenyl!benzyl-A82846B, wherein the 4- 4-chlorophenyl!benzyl is on the amino group of the 4 epi-vancosaminyl sugar of the 4-epi-vancosaminyl-O-glycosyl disaccharide or a salt thereof.”

This does two things for scope:

It narrows the “A82846B derivative” to a single substitution pattern: “4-(4-chlorophenyl)benzyl” installed on the amino group of the 4-epi-vancosaminyl sugar in the 4-epi-vancosaminyl-O-glycosyl disaccharide.
It creates an explicit formulation category: any dosage form with that active ingredient falls within the claim (assuming it is a “pharmaceutical composition” under applicable claim construction).

Practical scope implication: Claim 2 can cover branded or generic formulations that use this exact active species, including salts.

Claim 3-4: What treatments are covered, and which bacteria matters?

Claim 3 is a method-of-treatment claim:

“A method of treating a susceptible bacterial infection in an animal which comprises administering to the animal an antibacterially effective amount of a compound of claim 1 or a composition of claim 2.”

Claim 4 narrows to a specific target pathogen class:

“The bacterial infection comprises vancomycin-resistant enteroccoci.”

Practical scope implication: These claims target a use indication (VRE) in animal treatment. If accused products are used off-label for VRE, claim coverage can be argued on the administered compound and therapeutic effect rather than indication labeling, depending on jurisdiction and claim construction.

Claims 5-7: What synthesis route is claimed (and how tightly)?

Claims 5-7 are two related process claims, plus a dependent claim specifying the reducing agent.

Claim 5: Stepwise Schiff base then reduction

Reacting A82846B with 4’-chlorobiphenylcarboxaldehyde in a polar solvent.
Continue until formation of a Schiff’s base.
Reduce the Schiff’s base by addition of a reducing agent.

Claim 6: One-pot or simultaneous reduction with time sufficiency

React A82846B with 4’-chlorobiphenylcarboxaldehyde in polar solvent.
Presence of a reducing agent.
Time sufficient to produce the compound of claim 1.

Claim 7: Reducing agent specificity

Reducing agent is sodium cyanoborohydride.

Practical scope implication: Claims 5-6 cover the preparation chemistry with functional step requirements tied to Schiff base formation and reduction (for claim 5) or reduction under conditions sufficient to form the claimed compound (for claim 6). Claim 7 narrows further to a specific reductant. Process claims matter most when a competitor makes a near-variant compound using different conditions or aldehydes; they also provide leverage for discovery of manufacturing steps.

Scope map: what is “in” vs “out” based on the claim constraints

In scope (directly captured by claim language)

The exact final A82846B derivative corresponding to the claimed formula, including salts (claim 1).
A pharmaceutical composition containing the specified “4-(4-chlorophenyl)benzyl-A82846B” where the substituent is attached to the amino group of the 4-epi-vancosaminyl sugar (claim 2).
Use for treatment of susceptible bacterial infections in animals with antibacterially effective dosing, including VRE (claims 3-4).
Manufacturing by reductive amination of A82846B using 4’-chlorobiphenylcarboxaldehyde in polar solvent, via Schiff’s base formation and subsequent reduction (claim 5), or under reducing conditions sufficient to yield the product (claim 6), including sodium cyanoborohydride as reductant (claim 7).

Likely out of scope (key claim “escape hatches”)

Substitutions that change the aryl group identity. Because the aryl fragment is anchored to “4’-chlorobiphenylcarboxaldehyde,” replacing that aldehyde with a different substituted biphenyl carboxaldehyde likely produces a different final structure not captured by claim 1’s formula and not captured by claim 2’s “4-(4-chlorophenyl)benzyl” positional specification.
Substitutions that change the attachment site. Claim 2 specifies amino-group placement on the 4-epi-vancosaminyl sugar. A derivative that attaches at another functional handle (for example, altering O- vs N-linkage) is less likely to meet the explicit positional requirement for claim 2, and may not meet claim 1 if the structure differs.
Different synthesis routes that avoid the Schiff’s base/reductive amination logic tied to the named aldehyde. Even if the final product is the same, structural identity generally captures claim 1; however, process claims (5-7) can be avoided by using alternative methods that do not fall within the step requirements.
Method-of-treatment claims can be avoided by not using the compound for VRE treatment. A jurisdictional analysis may still matter, but claim 4’s narrowed target can be an operational constraint for generic labeling and clinical use.

Claim-by-claim infringement leverage for business decisions

Compound claim (claim 1)

Highest leverage for product competitors because it is a formula claim that does not require proof of manufacturing route.
For design-around, competitors must change the molecule enough to avoid matching the claimed formula and salts.

Composition claim (claim 2)

Captures finished dosage forms using the exact compound and exact placement on the vancosamine amino group.
If a competitor uses the same active ingredient but changes formulation excipients, claim 2 still tends to be satisfied because the claim does not require an excipient limitation beyond “pharmaceutical composition.”

Method claims (claims 3-4)

Create licensing or enforcement leverage if clinical and commercial use is aligned with VRE.
Claim 4 narrows the infection type; enforcement risk increases when marketing, compendial use, or clinical protocols focus on VRE.

Process claims (claims 5-7)

Useful for enforcement via manufacturing discovery, particularly if competitors attempt to argue a different synthetic origin.
Claim 7’s sodium cyanoborohydride specificity provides a narrower handle; claim 6’s “presence of a reducing agent” and “time sufficient” is broader than claim 7 but still anchored to the same aldehyde and polar solvent plus the overall production of the claimed compound.

Patent landscape: where 5,840,684 sits relative to typical A82846B derivative strategies

Without additional bibliographic data for the patent (publication number, filing date, assignee, listed related applications, priority chain, and cited art), the landscape can still be mapped at the level of technical claim islands that often show up across A82846B and similar glycopeptide-derived antibacterial programs.

Landscape cluster A: A82846B derivatives via reductive amination at the vancosamine amino group

US 5,840,684 is structurally positioned as a specific reductive amination product of:

scaffold: A82846B
aldehyde: 4’-chlorobiphenylcarboxaldehyde
transformation logic: Schiff base formation then reduction
attachment site: amino group on 4-epi-vancosaminyl sugar

This is a classic scaffold-modification cluster. Competitors commonly explore:

alternate aryl carboxaldehydes (different halogen substitution patterns; different biphenyl ring substitution; heteroaryl variants)
alternative reductants (so long as the final product still matches or avoids claim 1)
alternative solvents or conditions that change yields or impurity profiles, potentially allowing a manufacturing process design-around while still producing the same compound (where claim 1 would still block).

Landscape cluster B: Same chemistry, different target indications

The claims explicitly cover VRE. In the landscape, adjacent patents often broaden:

other Gram-positive resistant organisms beyond VRE
pediatric or veterinary use specifics
dosing regimens or combination therapy US 5,840,684’s method claims are indication-shaped but not regimen-shaped in your claim excerpt. That leaves space for other patents to own dosing schedules or combination regimens even if they do not own the core compound.

Landscape cluster C: Process-focused claims for manufacturing control

Claims 5-7 add another enforcement vector: manufacturing steps. In many antibiotic derivative families, later filings focus on:

improved reducing agents for cleaner conversion
alternative order-of-addition
avoiding isolation of Schiff’s base US 5,840,684 includes both a stepwise Schiff’s base pathway (claim 5) and a reducing-agent-in-process pathway (claim 6), which makes it harder to design around by claiming a wholly different sequence, but it still ties competitors to the aldehyde identity.

Scope boundaries that matter in enforcement and licensing

1) Structural capture vs route capture

Claim 1 and claim 2 dominate. If a competitor’s end product matches the formula and the sugar amino attachment pattern, product-level infringement risk is high regardless of how it is made.
Claims 5-7 matter more when the end product differs slightly but competitors are still making or testing close analogs with the same aldehyde transformation.

2) The aldehyde identity is a core anchor

Claims 5-6 name “4’-chlorobiphenylcarboxaldehyde.” That is a tight anchor for process design-around. However, the same anchor has less effect if claim 1 captures the final product regardless of synthesis route.

3) The sugar amino group placement is explicit

Claim 2’s location constraint is a key discriminant:

derivatives that attach at a different position or linkage do not meet that explicit language even if they are still “A82846B derivatives.”

4) VRE targeting is an operational trigger

Claim 4 creates enforcement pressure in markets where VRE is a stated or clinical-use indication. If products are not used for VRE, claim 4’s narrowed language becomes less relevant, though claim 3 still covers susceptible bacterial infection treatment.

Claim set in structured form (for quick diligence)

Claim	Type	Core subject matter	Scope anchor(s)
1	Compound	“compound of the formula” or salt	Final structure must match (structural capture)
2	Composition	pharmaceutical composition with “4-(4-chlorophenyl)benzyl-A82846B” with defined attachment	Active species identity + amino group placement on 4-epi-vancosaminyl sugar
3	Method	treat susceptible bacterial infection in animals; administer effective amount	Product from claim 1 or composition from claim 2
4	Method (narrow)	infection comprises vancomycin-resistant enterococci	VRE-specific use
5	Process	A82846B + 4’-chlorobiphenylcarboxaldehyde in polar solvent; form Schiff’s base; reduce	Aldehyde identity + Schiff base formation + reduction
6	Process	A82846B + 4’-chlorobiphenylcarboxaldehyde in polar solvent with reducing agent; time sufficient to form claim 1 compound	Aldehyde identity + reduction conditions
7	Process (narrow)	reducing agent is sodium cyanoborohydride	Specific reductant

Key Takeaways

US 5,840,684 centers on a specific A82846B derivative: a “4-(4-chlorophenyl)benzyl” substituent attached to the amino group of the 4-epi-vancosaminyl sugar of the disaccharide portion, sold or used as a pharmaceutical composition (claims 1-2).
The patent adds enforceable use coverage for animal treatment of susceptible infections and explicitly vancomycin-resistant enterococci (claims 3-4).
Two process routes are claimed for manufacturing the compound using 4’-chlorobiphenylcarboxaldehyde in polar solvent with Schiff’s base formation and reduction (claims 5-6), including sodium cyanoborohydride (claim 7).
Design-around is most feasible by altering the final molecule enough to avoid claim 1’s structural coverage and claim 2’s exact positional substitution, rather than relying solely on alternative synthesis routes, since structural claims typically dominate.

FAQs

1) Does US 5,840,684 protect the active ingredient only, or also finished products?

It protects both. Claim 1 covers the compound (and salts), and claim 2 covers pharmaceutical compositions containing that specific compound with defined placement on the vancosamine amino group.

2) What makes the substitution pattern in claim 2 especially important for infringement analysis?

Claim 2 explicitly requires that the “4-(4-chlorophenyl)benzyl” group sits on the amino group of the 4-epi-vancosaminyl sugar within the disaccharide structure. A different linkage or position is a core boundary.

3) Is the vancomycin-resistant enterococci language mandatory for all method coverage?

No. Claim 4 narrows to VRE, but claim 3 still covers methods for treating susceptible bacterial infections in animals using the claimed compound or composition. Claim 4 just specifies VRE.

4) Can a competitor avoid the process claims by changing the reducing agent?

They may avoid claim 7 if they do not use sodium cyanoborohydride, but claim 6 still covers the overall aldehyde-plus-reducing-agent chemistry if it produces the claimed compound. Product identity risk under claim 1 remains the main factor.

5) What is the core “chemical lever” for design-around efforts?

Change the final structure so it no longer matches the claimed formula and composition definition, or change the substitution position/linkage so it no longer places the “4-(4-chlorophenyl)benzyl” group on the specified amino handle.

References

[1] United States Patent 5,840,684 (claims as provided in the prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	248856	⤷ Start Trial
Austria	253077	⤷ Start Trial
Austria	266042	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,840,684

Summary for Patent: 5,840,684